Agios Pharmaceuticals (AGIO) EBT Margin (2012 - 2026)
Agios Pharmaceuticals (AGIO) posted EBT Margin of 712.22% for Q1 2026, down 30.4% on a QoQ basis from 546.18% in Q4 2025, and up 56518.0% year-over-year from N/an in Q1 2025.
Agios Pharmaceuticals (AGIO) EBT Margin (2012 - 2026) Analysis & Trends
Agios Pharmaceuticals' EBT Margin history runs 14 years deep, the most recent figure standing at 712.22% for Q1 2026.
- Quarterly EBT Margin rose 56518.0% year-over-year to 712.22% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 745.24% (down 256426.0% YoY) and the FY2025 annual result came in at 765.89%, down 273304.0% from the prior year.
- EBT Margin was 712.22% for Q1 2026 at Agios Pharmaceuticals, down from 546.18% in the prior quarter.
- Across five years, EBT Margin topped out at 11167.28% in Q3 2024 and bottomed at 12527.28% in Q1 2022.
- A 5-year average of 1255.24% and a median of 1277.4% in 2025 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2024 — EBT Margin surged 1240156 bps — and 2025, when it sank 1197033 bps.
- Agios Pharmaceuticals' EBT Margin stood at 2253.11% in 2022, then soared by 40 bps to 1350.7% in 2023, then advanced by 27 bps to 982.28% in 2024, then soared by 44 bps to 546.18% in 2025, then sank by 30 bps to 712.22% in 2026.
- Business Quant data shows AGIO's EBT Margin at 712.22% in Q1 2026, 546.18% in Q4 2025, and 803.05% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Agios Pharmaceuticals | 2.13 Bn | 2.13 Bn | 19.43 Mn | -712.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -712.22% |
| Dec 31, 2025 | -546.18% |
| Sep 30, 2025 | -803.05% |
| Jun 30, 2025 | -1,059.55% |
| Mar 31, 2025 | -1,277.40% |
| Dec 31, 2024 | -982.28% |
| Sep 30, 2024 | 11,167.28% |
| Jun 30, 2024 | -1,282.59% |
| Mar 31, 2024 | -1,181.16% |
| Dec 31, 2023 | -1,350.70% |
| Sep 30, 2023 | -1,234.27% |
| Jun 30, 2023 | -1,340.73% |
| Mar 31, 2023 | -1,551.83% |
| Dec 31, 2022 | -2,253.11% |
| Sep 30, 2022 | -2,607.85% |
| Jun 30, 2022 | -1,796.15% |
| Mar 31, 2022 | -12,527.28% |
| Dec 31, 2020 | -191.94% |
| Sep 30, 2020 | -228.13% |
| Jun 30, 2020 | -218.21% |